The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
EJHP Highlights: Narrow therapeutic index drug formulations in transplantation
The latest edition of the European Journal of Hospital Pharmacy (EJHP) includes an article on the 2012 EAHP Congress Satellite Symposium on the subject of narrow therapeutic index drug (NTID) formulations in transplantation.
The article explores the debate about regarding generic drug substitution in solid organ transplant recipients and the concerns about potential adverse consequences from uncontrolled switching between the different narrow therapeutic index drug (NTID) formulations now available to the physician and pharmacist.
The symposium included perspectives from a transplant organ patient and heard from Professor Atholl Johnston (Professor of Clinical Pharmacology, Barts and The London School of Medicine and Dentistry, UK) on the issues around the generic drug approval process and bioequivalence.
Professor Teun van Gelder (Erasmus University Medical Center, The Netherlands) discussed the recently published European Society for Organ Transplantation (ESOT) recommendations on generic substitution of immunosuppressive drugs.
Full article available here